These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 20731355

  • 1. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
    Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T.
    J Med Chem; 2010 Sep 23; 53(18):6595-602. PubMed ID: 20731355
    [Abstract] [Full Text] [Related]

  • 2. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
    Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC, Liou JP.
    J Med Chem; 2006 Oct 19; 49(21):6412-5. PubMed ID: 17034147
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
    Lee HY, Chang JY, Nien CY, Kuo CC, Shih KH, Wu CH, Chang CY, Lai WY, Liou JP.
    J Med Chem; 2011 Dec 22; 54(24):8517-25. PubMed ID: 22060033
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
    Xue N, Yang X, Wu R, Chen J, He Q, Yang B, Lu X, Hu Y.
    Bioorg Med Chem; 2008 Mar 01; 16(5):2550-7. PubMed ID: 18226907
    [Abstract] [Full Text] [Related]

  • 8. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
    Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV.
    J Med Chem; 2008 Mar 13; 51(5):1295-308. PubMed ID: 18260615
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ.
    Cancer Res; 2003 Jan 15; 63(2):513-21. PubMed ID: 12543810
    [Abstract] [Full Text] [Related]

  • 12. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.
    Mahal K, Biersack B, Caysa H, Schobert R, Mueller T.
    Invest New Drugs; 2015 Jun 15; 33(3):541-54. PubMed ID: 25678082
    [Abstract] [Full Text] [Related]

  • 13. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
    Pettit GR, Rhodes MR, Herald DL, Hamel E, Schmidt JM, Pettit RK.
    J Med Chem; 2005 Jun 16; 48(12):4087-99. PubMed ID: 15943482
    [Abstract] [Full Text] [Related]

  • 14. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
    Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, Lee CS, Kang HR, Ahn SK, Moon SK, Kim DH, Lee S, Choi NS, Lee KJ.
    J Med Chem; 2010 Sep 09; 53(17):6337-54. PubMed ID: 20690624
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
    O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.
    J Med Chem; 2010 Dec 23; 53(24):8569-84. PubMed ID: 21080725
    [Abstract] [Full Text] [Related]

  • 16. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
    Odlo K, Hentzen J, dit Chabert JF, Ducki S, Gani OA, Sylte I, Skrede M, Flørenes VA, Hansen TV.
    Bioorg Med Chem; 2008 May 01; 16(9):4829-38. PubMed ID: 18396050
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
    Arthuis M, Pontikis R, Chabot GG, Seguin J, Quentin L, Bourg S, Morin-Allory L, Florent JC.
    ChemMedChem; 2011 Sep 05; 6(9):1693-705. PubMed ID: 21732536
    [Abstract] [Full Text] [Related]

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 19. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
    Simoni D, Romagnoli R, Baruchello R, Rondanin R, Grisolia G, Eleopra M, Rizzi M, Tolomeo M, Giannini G, Alloatti D, Castorina M, Marcellini M, Pisano C.
    J Med Chem; 2008 Oct 09; 51(19):6211-5. PubMed ID: 18783207
    [Abstract] [Full Text] [Related]

  • 20. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
    Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T.
    J Med Chem; 1998 Jul 30; 41(16):3022-32. PubMed ID: 9685242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.